ONGC and Oil India are key beneficiaries if Brent price remains elevated above USD 70/bbl as their CMP is discounting ~USD 65/bbl net crude realisation amidst low risk of windfall tax, said analysts.
The RBI has issued final guidelines for transitioning to an Expected Credit Loss (ECL) framework, effective April 1, 2027, largely in line with the earlier draft.
Analysts at JM Financial Institutional Securities have pegged an upside target of ₹393 per share on BHEL; whereas Axis Securities expects SAIL to rally toward ₹200-mark.
Sun Pharma to acquire all outstanding shares of Organon for $14.00 per share in an all cash transaction with an enterprise valuation of $11.75 billion.
The average trading volumes at the Shaily Engineering counter more than doubled with a combined 1.5 million shares changing hands on the NSE and BSE in Friday's intra-day trade.
The company will continue to derive strength from the existence of experienced promoters and positive outlook for the GLP1 segment, which is expected to yield revenue to the company from FY27 onwards.
The company has traditionally been stronger on debt side while on equity side, it has consistently been losing market share for which the stock trades at a considerable discount to other larger peers.
In the past month, Azad Engineering shares have zoomed 51 per cent, as against a 6 per cent fall in the benchmark Sensex.
Himadri Speciality said it has decided to remain firmly focused on disciplined capital allocation to drive sustainable returns and maintain a robust ROCE profile.
With strong policy environment, rising defence allocations, increasing indigenization and a clear shift towards advanced electronics and systems, Data Patterns is well-positioned to benefit.
With healthy revenue growth, a strong order book, and a sustained execution pipeline, BHEL enters FY2026-27 with solid momentum.
The Nifty Auto index has declined nearly 3% in the last two trading sessions amid a fresh spike in Brent oil prices owing to the US-Iran standoff.
Glenmark Pharma, Cipla, Wockhardt, Mankind Pharma, Lupin, Zydus Life, Laurus, Ipca Labs, Divis Labs, Strides Pharma and Onesource were up in the range of 3% to 6%.
The brokerage firm expects UTLSOLAR to deliver strong growth (56 per cent/65 per cent/65 per cent CAGR in revenue/EBITDA/PAT over FY25-28), driven by PMSGMBY-led demand and capacity expansion.
Andrew Holland, head - new asset class, Nippon India Asset Management in a Q&Q with Puneet Wadhwa says that the markets are assuming that the West Asia conflict won't be prolonged.
In the near-term, the non-gold portfolio will continue to consolidate before resuming growth momentum in a calibrated manner from FY27 onwards, analysts at Axis Securities said in the Q3 result update
ABB India, Samvardhana Motherson International and Adani Power from the Nifty Next 50 index surged in the range of 5 per cent to 8 per cent in intra-day deals on Wednesday.
As early signs of commodity inflation return to the FMCG basket, analysts at ICICI Securities believe HUL is structurally better positioned to navigate the cycle.
Thus far in the month of April, the market price of Adani Power has zoomed 35 per cent in anticipation of healthy demand outlook.
The order book at ₹5,005 crore remains significantly below earlier guidance of ~₹8,000 crore, highlighting weaker order inflows and cautious order booking strategy, ICICI Securities said in a note.